Argent BioPharma (ASX:RGT) signed a binding term sheet with David Trading to operate its facility in Malta for a 49-year term, according to a Wednesday filing with the Australian bourse.
The plant, which specializes in liquid dose form production for anti-inflammatory treatment CimetrA, can produce thousands of units per day, the filing said.
David Trading will bear all financial and operational responsibilities for the facility, including all debts and liabilities incurred from the signing date forward, per the filing.
Argent BioPharma shares were down 5% in afternoon trade Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.